

FORM PTO-1449

U.S. Dept. of Commerce

Atty Docket No.

Serial No.

P1085R6

09/489,394

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Patent and Trademark Office

Applicant


Hsei et al.

Filing Date

21 Jan 2000

Group

1642



ATTACH TO # 8

PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
Lm ↓ L66	1	4,002,531	11.01.77	Royer	—	—	
	2	4,179,337	18.12.79	Davis et al.			
	3	4,515,893	07.05.85	Kung et al.			
	4	4,732,863	22.03.88	Tomasi et al.			
	5	5,091,313	25.02.92	Chang, T.			
	6	5,147,537	15.09.92	Sada et al.			
	7	5,166,322	24.11.92	Shaw et al.			
	8	5,169,627	08.12.92	Cunningham-Rundles			
	9	5,527,528	18.06.96	Allen et al.			
	10	5,532,150	02.07.96	Snow et al.			
	11	5,595,732	21.01.97	Hakini et al.			
	12	5,618,920	08.04.97	Robinson et al.			
	13	5,620,689	15.04.97	Allen et al.			
	14	5,622,700	22.04.97	Jardieu et al.			
	15	5,643,575	01.07.97	Martinez et al.			
	16	5,661,020	26.08.97	Snow et al.			
	17	5,670,132	23.09.97	Griffiths et al.			
	18	5,672,347	30.09.97	Aggarwal et al.			
	19	5,677,426	14.10.97	Fong et al.			
	20	5,679,532	21.10.97	Repine, J.			
	21	5,686,070	11.11.97	Doerschuk et al.			
	22	5,693,762	02.12.97	Queen et al.			
	23	5,695,760	09.12.97	Faanes et al.			
	24	5,698,196	16.12.97	Matsushima et al.			
	25	5,702,946	30.12.97	Doerschuk et al.			
	26	5,707,622	13.01.98	Fong et al.			
	27	5,714,338	03.02.98	Wai Fei et al.			
	28	5,725,856	10.03.98	Hudziak et al.			
	29	5,726,037	10.03.98	Bodary et al.			
	30	5,766,897	16.06.98	Braxton, S.			
	31	5,874,080	23.02.99	Hebert et al.			

Examiner

Date Considered

3/18/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce

Atty Docket No.

Serial No.

P1085R6

09/489,394

Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Hsei et al.

Filing Date

21 Jan 2000

Group

1642

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	32	420,937 B1	09.11.94	EPO	—	—	
	33	770,628	02.05.97	EPO			
	34	WO 92/04372	19.03.92	PCT	7		
	35	WO 93/04173	04.03.93	PCT			
	36	WO 94/11026	26.05.94	PCT			
	37	WO 94/12219	09.06.94	PCT			
	38	WO 94/21235	29.09.94	PCT			
	39	WO 95/11987	04.05.95	PCT			
	40	WO 95/15769	15.06.95	PCT			
	41	WO 95/23813	08.09.95	PCT			
	42	WO 95/23865	08.09.95	PCT			
	43	WO 95/32003	30.11.95	PCT			
	44	WO 96/02576	01.02.96	PCT (ENGLISH ABSTRACT ATTACHED)			
	45	WO 96/09325	28.03.96	PCT			
	46	WO 96/22785	01.08.96	PCT			
	47	WO 96/34015	31.10.96	PCT			
	48	WO 96/40210	19.12.96	PCT			
	49	WO 96/40731	19.12.96	PCT			
	50	WO 97/01354	16.01.97	PCT			
	51	WO 97/10847	27.03.97	PCT			
	52	WO 97/26912	31.07.97	PCT			
	53	WO 97/40215	30.10.97	PCT (ENGLISH ABSTRACT ATTACHED)			
	54	WO 98/06248	19.02.98	PCT			
	55	WO 98/23761	04.06.98	PCT			
	56	WO 98/25971	18.06.98	PCT			
	57	WO 98/37200	27.08.98	PCT			
	58	WO 98/45331	15.10.98	PCT			
	59	WO 98/51793	19.11.98	PCT			
	60	WO 99/01556	14.01.99	PCT			
	61	WO 99/37779	29.07.99	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

LA	62	Abuchowski and Davis, "Soluble Polymer- Enzyme Adducts" <u>Enzymes as Drugs</u> , Holcenberg, JS; Roberts, J eds., New York: Wiley, Chapter 13, pps. 367-383 (1981)
LA	63	Adagen Label <u>Physicians' Desk Reference</u> (Product Information), 48 edition, Montvale, NJ: Medical Economics Data Production Company pps. 917-918 (1994)
LA	64	Allen et al., "A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells" <u>Biochimica et Biophysica Acta</u> 1237(2):99-108 (Jul 26, 1995)

Examiner

Date Considered

3/18/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1085R6

Serial No.

09/489,394

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Hsei et al.

Filing Date

21 Jan 2000

Group

1642

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

LMP	65	Anderson and Tomasi, "Polymer modification of antibody to eliminate immune complex and Fc binding" <u>Journal of Immunological Methods</u> 109(1):37-42 (Apr 22, 1988)
	66	Beauchamp et al., "A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and α_2 -macroglobulin" <u>Analytical Biochemistry</u> 131(1):25-33 (1983)
	67	Bernard et al., "The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination" <u>American Journal of Respiratory & Critical Care Medicine</u> 149(3 Pt 1):818-824 (Mar 1994)
	68	Brooks and Stocks, "Use of polyacrylamide-derivatized antibody in dextran-poly(ethylene glycol) systems" <u>Methods in Enzymology</u> 228:390-395 (1994)
	69	Brumeanu et al., "Derivatization with monomethoxypolyethylene glycol of Igs expressing viral epitopes obviates adjuvant requirements" <u>Journal of Immunology</u> 154(7):3088-3095 (Apr 1, 1995)
	70	Carter et al., "Preparation and uses of Fab' fragments from Escherichia coli" <u>Antibody Engineering: a Practical Approach</u> , Hoogenboom, H., McCafferty, J., Chiswell, D. eds., Oxford, UK: IRL Press, Chapter 13, pps. 291-308 (1996)
	71	Chamow et al., "Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation" <u>Bioconjugate Chemistry</u> 5(2):133-140 (Mar-Apr 1994)
	72	Chapman et al., "Therapeutic antibody fragments with prolonged in vivo half-lives" <u>Nature Biotechnology</u> 17(8):780-783 (Aug 1999)
	73	Clark et al., "Long-acting growth hormones produced by conjugation with polyethylene glycol" <u>Journal of Biological Chemistry</u> 271(36):21969-21977 (Sep. 6, 1996)
	74	Cunningham-Rundles et al., "Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation" <u>Journal of Immunological Methods</u> 152(2):177-190 (Aug 10, 1992)
	75	Davis et al., "Soluble, Nonantigenic Polyethylene Glycol-Bound Enzymes" <u>Biomedical Polymers: Polymeric Materials and Pharmaceuticals for Biomedical Use</u> , Goldberg, E and Nakajima, A eds., New York: Academic Press pps. 441-452 (1980)
	76	Delgado et al., "Analytical partitioning of poly(ethylene glycol)-modified proteins" <u>Journal of Chromatography B</u> 692(2):263-272 (May 9, 1997)
	77	Delgado et al., "Distinct Influence of PEGylation on the Tumour Localisation of Transferrin and a Tumour-Specific Fab Fragment (F9)" <u>Journal of Cellular Biochemistry</u> (Abstr. A4-101, Keystone Symposium held at Hilton Head Island, SC, Jan 7-13 1995) Suppl. 19A:171 (1995)
	78	Delgado et al., "Enhanced tumour specificity of an anti-carcinoembryonic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification" <u>British Journal of Cancer</u> 73(2):175-182 (Jan 1996)
	79	Delgado et al., "The uses and properties of PEG-linked proteins" <u>Critical Reviews in Therapeutic Drug Carrier Systems</u> 9(3-4):249-304 (1992)
	80	Deuel et al., "Amino acid sequence of human platelet factor 4" <u>Proc. Natl. Acad. Sci.</u> 74:2256-2258 (1977)
	81	Donnelly et al., "Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups" <u>Lancet</u> 341(8846):643-647 (Mar 13, 1993)
	82	Elling and Kula, "Immunoaffinity partitioning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies" <u>Biotechnology and Applied Biochemistry</u> 13(3):354-362 (Jun 1991)
↙	83	Eno-Amooquaye et al., "Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol" <u>British Journal of Cancer</u> 73(11):1323-1327 (Jun 1996)
LA	84	Folkesson et al., "Acid aspiration-induced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms" <u>Journal of Clinical Investigation</u> 96(1):107-116 (Jul 1995)

Examiner

Date Considered

3/18/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1085R6	Serial No. 09/489,394
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Hsei et al.	
				Filing Date 21 Jan 2000	Group 1642
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
85	Gonzalez et al., "Humanization of Murine 6G425: An Anti-IL8 Monoclonal Antibody Which Blocks Binding of IL8 to Human Neutrophils" 1996 Keystone Symposia on Exploring and Exploiting Antibody and Ig Superfamily Combining Sites (Poster) pps. 1-21 (February 1996)				
86	Harding et al., "Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes" <u>Biochimica et Biophysica Acta</u> 1327(2):181-192 (Jul 25, 1997)				
87	Harris et al., "Synthesis and Characterization of Poly(ethylene Glycol) Derivatives" <u>J. Polym. Sci., Polym. Chem. Ed.</u> 22(2):341-352 (1984)				
88	Haselgrubler et al., "Synthesis and applications of a new poly(ethylene glycol) derivative for the crosslinking of amines with thiols" <u>Bioconjugate Chemistry</u> 6(3):242-248 (May-Jun 1995)				
89	Hebert et al., "Endothelial and Leukocyte Forms of IL-8: Conversion by Thrombin and Interactions with Neutrophils" <u>J. Immunol.</u> 145(9):3033-3040 (Nov 1, 1990)				
90	Hebert et al., "Interleukin-8: A Review" <u>Cancer Investigation</u> 11(6):743-750 (1993)				
91	Hebert, C., "Humanized anti IL-8 antibodies: potential therapy for shock and ARDS?" (Summary of seminar presented at the 1997 Keystone Symposia on "The Role of Chemokines in Leukocyte Trafficking and Disease" held at the Copper Mountain Resort, CO on March 31-April 5, 1997.) pps. 4				
92	Holliger et al., "Diabodies": Small bivalent and bispecific antibody fragments" <u>Proc. Natl. Acad. Sci. USA</u> 90:6444-6448 (Jul 1993)				
93	Karr et al., "Use of poly(ethylene glycol)-modified antibody in cell extraction" <u>Methods in Enzymology</u> 228:377-390 (1994)				
94	Katre N., "The Conjugation of Proteins with Polyethylene Glycol and other Polymers. Altering properties of proteins to enhance their therapeutic potential." <u>Advanced Drug Delivery Reviews</u> 10(1):91-114 (1993)				
95	Kawamura et al., "Immune responses to polyethylene glycol modified L-asparaginase in mice" <u>International Archives of Allergy & Applied Immunology</u> 76(4):324-330 (1985)				
96	Kirpotin et al., "Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro" <u>Biochemistry</u> 36(1):66-75 (Jan 7, 1997)				
97	Kitamura et al., "Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy" <u>Cancer Research</u> 51(16):4310-4315 (Aug 15, 1991)				
98	Kitamura et al., "Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization" <u>Biochemical & Biophysical Research Communications</u> 171(3):1387-1394 (Sep 28, 1990)				
99	Knauf et al., "Relationship of Effective Molecular Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water Soluble Polymers" <u>The Journal of Biological Chemistry</u> 263(29):15064-15070 (Oct 15, 1988)				
100	Ko et al., "A sensitive enzyme-linked immunosorbent assay for human interleukin-8" <u>J. Immunol. Methods</u> 149:227-235 (1992)				
101	Koumenis et al., "Tailoring antibody fragments with PEGylation without loss in biological activity" <u>Protein Science</u> (Abstract 109-M, presented at the Protein Society's Twelfth Symposium in San Diego, CA on July 25-29, 1998) 7(Suppl. 1):73 (Jul 1998)				
102	Lang et al., "Suppression of antibody responses in rats to murine anti-CD4 monoclonal antibodies by conjugates with monomethoxypolyethylene glycol" <u>Immunology Letters</u> 32(3):247-252 (May 1992)				
103	Lee and Sehon, "Suppression of reaginic antibodies with modified allergens. I. Reduction in allergenicity of protein allergens by conjugation to polyethylene glycol" <u>International Archives of Allergy & Applied Immunology</u> 56(2):159-170 (1978)				
104	Mainolfi, E. et al., "Reduction of Immunogenicity of A Murine ANTI-ICAM-1 Antibody Through Pegylation Chemistry" <u>The 9th International Congress of Immunology (abstract book)</u> (abstract #5247) pps. 885 (1995)				
Examiner				Date Considered	
				3/18/03	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1085R6	Serial No. 09/489,394
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Hsei et al.	
				Filing Date 21 Jan 2000	Group 1642
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
LPP	105	Maiti et al., "Tolerogenic conjugates of xenogeneic monoclonal antibodies with monomethoxypolyethylene glycol. I. Induction of long-lasting tolerance to xenogeneic monoclonal antibodies" <u>International Journal of Cancer Suppl.</u> 3:17-22 (1988)			
	106	Maruyama et al., "Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo" <u>FEBS Letters</u> 413(1):177-180 (Aug 11, 1997)			
	107	Maruyama et al., "Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals" <u>Advanced Drug Delivery Reviews</u> 24:235-242 (1997)			
	108	Matsumoto et al., "Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8" <u>Laboratory Investigation</u> 77(2):119-125 (Aug 1997)			
	109	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" <u>Nature</u> 348:552-554 (1990)			
	110	Mulligan et al., "Inhibition of Lung Inflammatory Reactions in Rats by an Anti-Human IL-8 Antibody" <u>J. Immunol.</u> 150(12):5585-5595 (June 15, 1993)			
	111	Nordvall et al., "IgG and IgE antibody patterns after immunotherapy with monomethoxy polyethyleneglycol modified honey bee venom" <u>Allergy: European Journal of Allergy & Clinical Immunology</u> 41(2):89-94 (Feb 1986)			
	112	Pedley et al., "The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody" <u>British Journal of Cancer</u> 70(6):1126-1130 (Dec 1994)			
	113	Sekido et al., "Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8" <u>Nature</u> 365:654-657 (October 14, 1993)			
	114	Shahinian and Silviu, "A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes" <u>Biochimica et Biophysica Acta</u> 1239(2):157-167 (Nov 1, 1995)			
	115	Sharp et al., "Synthesis and application of a poly(ethylene glycol)-antibody affinity ligand for cell separations in aqueous polymer two-phase systems" <u>Analytical Biochemistry</u> 154(1):110-117 (Apr 1986)			
	116	(Shearwater Polymers, Inc.'s January 1996 Catalog of Polyethylene Glycol Derivatives) pps. 1-50			
	117	St. John et al., "Immunologic Therapy for ARDS, Septic Shock, and Multiple-Organ Failure" <u>Chest</u> 103:932-943 (1993)			
	118	Sticherling et al., "Immunohistochemical studies on NAP-1/IL-8 in contact eczema and atopic dermatitis" <u>Arch. Dermatol. Res.</u> 284:82-85 (1992)			
	119	Sticherling et al., "Production and Characterization of Monoclonal Antibodies Against the Novel Neutrophil Activating Peptide NAP/IL-8" <u>J. Immunol.</u> 143(5):1628-1634 (September 1, 1989)			
	120	Suzuki et al., "Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobulin G. Part II. Effect of molecular weight of poly(ethylene glycol)" <u>Journal of Biomaterials Science, Polymer Edition</u> 1(2):71-84 (1989)			
	121	Suzuki et al., "Preparation and characteristics of magnetite-labelled antibody with the use of poly(ethylene glycol) derivatives" <u>Biotechnology & Applied Biochemistry</u> 21(Pt 3):335-345 (Jun 1995)			
	122	Tanaka et al., "Synthesis and biological characterization of monocyte-derived neutrophil chemotactic factor" <u>FEBS letters</u> 236(2):467-470 (Aug 1988)			
	123	Van Damme et al., "Purification of granulocyte chemotactic peptide/interleukin-8 reveals N-terminal sequence heterogeneity similar to that of β -thromboglobulin" <u>European Journal of Biochemistry</u> 181:337-344 (1989)			
LPP	124	Veronese et al., "Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol)" <u>Journal of Controlled Release</u> 40:199-209 (1996)			
Examiner				Date Considered	
				3/18/03	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FCRM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Attv Docket No.

P1085R6

Serial No.

09/489,394

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Hsei et al.

Filing Date

21 Jan 2000

Group	Mean	SD	95% CI	95% CI	95% CI
1	1.00	0.00	1.00	1.00	1.00
2	1.00	0.00	1.00	1.00	1.00
3	1.00	0.00	1.00	1.00	1.00
4	1.00	0.00	1.00	1.00	1.00
5	1.00	0.00	1.00	1.00	1.00
6	1.00	0.00	1.00	1.00	1.00
7	1.00	0.00	1.00	1.00	1.00
8	1.00	0.00	1.00	1.00	1.00
9	1.00	0.00	1.00	1.00	1.00
10	1.00	0.00	1.00	1.00	1.00
11	1.00	0.00	1.00	1.00	1.00
12	1.00	0.00	1.00	1.00	1.00
13	1.00	0.00	1.00	1.00	1.00
14	1.00	0.00	1.00	1.00	1.00
15	1.00	0.00	1.00	1.00	1.00
16	1.00	0.00	1.00	1.00	1.00
17	1.00	0.00	1.00	1.00	1.00
18	1.00	0.00	1.00	1.00	1.00
19	1.00	0.00	1.00	1.00	1.00
20	1.00	0.00	1.00	1.00	1.00
21	1.00	0.00	1.00	1.00	1.00
22	1.00	0.00	1.00	1.00	1.00
23	1.00	0.00	1.00	1.00	1.00
24	1.00	0.00	1.00	1.00	1.00
25	1.00	0.00	1.00	1.00	1.00
26	1.00	0.00	1.00	1.00	1.00
27	1.00	0.00	1.00	1.00	1.00
28	1.00	0.00	1.00	1.00	1.00
29	1.00	0.00	1.00	1.00	1.00
30	1.00	0.00	1.00	1.00	1.00
31	1.00	0.00	1.00	1.00	1.00
32	1.00	0.00	1.00	1.00	1.00
33	1.00	0.00	1.00	1.00	1.00
34	1.00	0.00	1.00	1.00	1.00
35	1.00	0.00	1.00	1.00	1.00
36	1.00	0.00	1.00	1.00	1.00
37	1.00	0.00	1.00	1.00	1.00
38	1.00	0.00	1.00	1.00	1.00
39	1.00	0.00	1.00	1.00	1.00
40	1.00	0.00	1.00	1.00	1.00
41	1.00	0.00	1.00	1.00	1.00
42	1.00	0.00	1.00	1.00	1.00
43	1.00	0.00	1.00	1.00	1.00
44	1.00	0.00	1.00	1.00	1.00
45	1.00	0.00	1.00	1.00	1.00
46	1.00	0.00	1.00	1.00	1.00
47	1.00	0.00	1.00	1.00	1.00
48	1.00	0.00	1.00	1.00	1.00
49	1.00	0.00	1.00	1.00	1.00
50	1.00	0.00	1.00	1.00	1.00
51	1.00	0.00	1.00	1.00	1.00
52	1.00	0.00	1.00	1.00	1.00
53	1.00	0.00	1.00	1.00	1.00
54	1.00	0.00	1.00	1.00	1.00
55	1.00	0.00	1.00	1.00	1.00
56	1.00	0.00	1.00	1.00	1.00
57	1.00	0.00	1.00	1.00	1.00
58	1.00	0.00	1.00	1.00	1.00
59	1.00	0.00	1.00	1.00	1.00
60	1.00	0.00	1.00	1.00	1.00
61	1.00	0.00	1.00	1.00	1.00
62	1.00	0.00	1.00	1.00	1.00

1642

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Date Considered

3/18/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.